All News
🧨 Factors associated w/ Pulmonary Embolism in ORAL surveillance:
⚡️history of VTE ⚡️antidepressant use
⚡️BMI≥30
⚡️corticosteroid use
⚡️male gender
⚡️age ≥65
⚡️Hx of Hypertension
⚡️hormonal ttmt use
POS0239 #EULAR2022 @RheumNow https://t.co/pT6MDAUbjH
Aurelie Najm AurelieRheumo ( View Tweet)
Prof van Lear reviews #EULAR ’s 11 points to consider for difficult to treat RA (D2T RA) published here https://t.co/zOLiMChjx8 #EULAR2022 @rheumnow (1/n) https://t.co/mVjJ5A1VkW
TheDaoIndex KDAO2011 ( View Tweet)
Dr. E. Loza reminds #EULAR2022 that it is important to measure response of patients when using clinical guidelines for treatment! It will help us adapt guidelines for the future to help patients. @RheumNow https://t.co/pMkpsMH44U
Dr. Rachel Tate uptoTate ( View Tweet)
The reference is at https://t.co/Auwrimc0jt
Dr. Antoni Chan synovialjoints ( View Tweet)
Eun et al. South Korean population based study. n=138,592 RA patients. aHR dementia 1.19 (95%CI 1.16–1.23), Alzheimers 1.21 (95%CI 1.67-1.25), Vascular dementia 1.10 (95%CI 0.99-1.21) @RheumNow #EULAR2022 OP0271 https://t.co/URNYnYzuF6
Links:
Richard Conway RichardPAConway ( View Tweet)
Razmjou et al. Survival in RA-ILD patients with lung transplant comparable to other cohorts. Not surprisingly UIP pattern trended to worse outcome HR 7.13, p=0.06 @RheumNow #EULAR2022 OP0275 https://t.co/RJ1nMkHwRh https://t.co/iUENMhqiX3
Links:
Richard Conway RichardPAConway ( View Tweet)
Case reports of tofacitinib efficacy for calcinosis over last couple of years. Benefits were relatively quickly (within 3m) reported by Jiri Vencovsky #eular2022
Alberta Hoi alberta_hoi ( View Tweet)
Lisa Rider suggests that calcinosis is more commonly seen in JDM than adults maybe the result of the more prominent vasculopathy and IFN signature. #EULAR2022
Alberta Hoi alberta_hoi ( View Tweet)
Always satisfying to see the big plenary hall in full flight #EULAR2022 @RheumNow https://t.co/DkzZCFvFw7
David Liew drdavidliew ( View Tweet)
SLE trials update
Translating targeted therapy from bench to bedside has been more problematic in SLE than other autoimmune diseases.
https://t.co/xmYbgOplsm https://t.co/QUrtwAJqNl
Links:
Dr. John Cush RheumNow ( View Tweet)
Jacob van Laar on difficult to treat (D2T) RA. Comorbidities, fibromyalgia, obesity contribute to this. Associated with pauci-immune synovial pathotype. A consensus definition of D2T developed and est 5-20% of RA meet this criteria #EULAR2022 @RheumNow https://t.co/MgxJIJgxYw
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2022 Difficult to treat RA (D2TRA):
Synovial pathotype shows a pauci-immune phenotype, different from other forms of RA
@RheumNow https://t.co/0osG5Bb5yb
Eric Dein ericdeinmd ( View Tweet)
#EULAR2022 Difficult to treat RA
Which is the only independent risk factor in Netherlands study for D2TRA?
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Those #EULAR2022 vaccination bracelets are not the most discrete of things (and you can’t take them off). https://t.co/02NrLcqzT2
Francois Nantel FNantel ( View Tweet)
POS0130 from #EULAR2022 found only a 50% concordance between PsO patients with self-reported MSK pain and US findings of PsA. Remember, not all pain in PsO is PsA. @RheumNow https://t.co/CiMUa9HNgk
Dr. Rachel Tate uptoTate ( View Tweet)
🦶🏼What drives positivity of famous Squeeze test in MTPs in RA?
MRI correlation study finds:
-in early RA, association w/
*Synovitis OR 3.2 and Inter-metatarsal bursitis OR 4.8
-in pts in remission
*Sub clinical synovitis only OR 2.5
@RheumNow #EULAR2022
OP0290 https://t.co/2CNUsaesaG
Aurelie Najm AurelieRheumo ( View Tweet)
Prof van Lear defines Difficult to Treat (D2T) RA:
Failed >2 b/tsDMARD w/diff't MOA after failing csDMARD AND signs of active/progressing disease: DAS28 ESR >3.2 or CDAI>10, high ESR/CRP, imaging, Sx's causing low QoL, pred>7.5 mg/d, rapid xray progression #EULAR2022 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Difficult to treat RA? #EULAR2022
1) Active/progressive disease, unable to taper steroids, radiographic progressive, decreased QoL
2) Failure of medications (2+ b/tsDMARD after csDMARD)
3) Physician/patient perception
- Fatigue: not part of definition
~5-20% pts
@Rheumnow https://t.co/i5sfwoF2Gs
Eric Dein ericdeinmd ( View Tweet)
When will this madness stop!? TNFi to treat OA (yet again). Adalimumab for "inflammatory" knee OA. And again it doesn't work. @RheumNow #EULAR2022 OP0229 https://t.co/htwyLTYwG4
Links:
Richard Conway RichardPAConway ( View Tweet)
#POS0787 #EULAR2022 More data to support the association of Anti-Ribosomal P ab with Depression + Cognitive Dysfunction using functional MRI in #lupus. To screen for neuropsychiatric in ab+ patients @RheumNow https://t.co/9JQDImrHAt
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)